Cargando…
CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CA...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274832/ https://www.ncbi.nlm.nih.gov/pubmed/34262333 http://dx.doi.org/10.2147/IJGM.S318278 |
_version_ | 1783721611240669184 |
---|---|
author | Meng, Quan Li, Can-Xuan Long, Dan |
author_facet | Meng, Quan Li, Can-Xuan Long, Dan |
author_sort | Meng, Quan |
collection | PubMed |
description | AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CARS expression patterns in ccRCC, its relationship with clinicopathological variables, and prognosis of ccRCC and potential biological mechanisms in ccRCC. RESULTS: CARS was significantly elevated in ccRCC. Overexpression of CARS indicated disease progression. Univariate and multivariate Cox regression analyses identified CARS as an independent prognostic factor for overall survival (OS) in renal clear cell carcinoma. Mechanically, CARS influenced the progression of ccRCC through several tumor-related pathways. Additionally, we found that CARS was significantly associated with tumor mutational burden, tumor-infiltrating immune cells, immunosuppressive molecules, methyltransferases, and mismatch repair proteins. CONCLUSION: CARS could serve as a promising prognostic biomarker and therapeutic target for ccRCC. |
format | Online Article Text |
id | pubmed-8274832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82748322021-07-13 CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity Meng, Quan Li, Can-Xuan Long, Dan Int J Gen Med Original Research AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CARS expression patterns in ccRCC, its relationship with clinicopathological variables, and prognosis of ccRCC and potential biological mechanisms in ccRCC. RESULTS: CARS was significantly elevated in ccRCC. Overexpression of CARS indicated disease progression. Univariate and multivariate Cox regression analyses identified CARS as an independent prognostic factor for overall survival (OS) in renal clear cell carcinoma. Mechanically, CARS influenced the progression of ccRCC through several tumor-related pathways. Additionally, we found that CARS was significantly associated with tumor mutational burden, tumor-infiltrating immune cells, immunosuppressive molecules, methyltransferases, and mismatch repair proteins. CONCLUSION: CARS could serve as a promising prognostic biomarker and therapeutic target for ccRCC. Dove 2021-07-06 /pmc/articles/PMC8274832/ /pubmed/34262333 http://dx.doi.org/10.2147/IJGM.S318278 Text en © 2021 Meng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Meng, Quan Li, Can-Xuan Long, Dan CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title | CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title_full | CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title_fullStr | CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title_full_unstemmed | CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title_short | CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity |
title_sort | cars as a prognosis factor in clear cell renal cell carcinoma and its association with tumor immunity |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274832/ https://www.ncbi.nlm.nih.gov/pubmed/34262333 http://dx.doi.org/10.2147/IJGM.S318278 |
work_keys_str_mv | AT mengquan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity AT licanxuan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity AT longdan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity |